Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)

Status: Recruiting
Phase: N/A
Diagnosis: Kidney Cancer
NCT ID: NCT00749320 (View complete trial on
DFCI Protocol ID: 08-078


The purpose of this study is to assess magnetic resonance imaging (MRI) as a tool to track tumor growth for renal cell carcinoma while the participant is receiving clinical treatment therapy with sunitinib or pazopanib. An MRI is a sophisticated type of scan that uses powerful magnets to make clearer images or to focus on detailed medical information in the participants abdomen and pelvis. This imaging done for this study will use the ASL MRI technique that allows us to see blood flow changes which possibly may indicated tumor growth.


Conducting Institutions:
Dana-Farber Cancer Institute, Beth-Israel Deaconess Medical Center, Brigham and Women's Hospital

Overall PI:
Toni Choueiri, MD, Dana-Farber Cancer Institute

Site-responsible Investigators:
Rupal Bhatt, MD, Beth Israel Deaconess Medical Center

Beth-Israel Deaconess Medical Center: Cancer Trials Call Center, 617-667-3060
Dana-Farber Cancer Institute: Judith Prisby, 617-632-5068,
Dana-Farber Cancer Institute: Amanda Fredericks, 617-632-5514,
Dana-Farber Cancer Institute: Meghara Walsh, 617-632-5264,

Eligibility Criteria

Inclusion Criteria: - Patients diagnosed with metastatic renal cell carcinoma and who will initiate sunitinib - Enrolled on protocol 06-105, "Collection of specimens and clinical data from patients with renal cell carcinoma treated with targeted therapies" - Found to have tumors that are 2.5cm or greater as determined by CT imaging - Candidate lesions for ASL MRI should be 2.5cm or greater. Order of preference of lesion location will be as follows: abdominal lesions, bone lesions and chest lesions Exclusion Criteria: - Contraindication to MRI
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms